NIH funds Celdara for pandemic influenza antiviral development

By The Science Advisory Board staff writers

August 12, 2020 -- The U.S. National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases has awarded Celdara Medical a Small Business Innovation Research (SBIR) grant for the development of antivirals against pandemic and interpandemic influenzas.

The funding will support proof-of-concept efforts through Celdara's Pandemic Security Initiative. The initiative is a framework for public-private partnerships that incorporates science, entrepreneurship, public-sector investment, and private-sector business acumen to develop and produce treatments and vaccines that will address future pandemic threats.

Celdara's Academic Partner Network includes collaborations with 60 leading universities, and thousands of pipeline innovations from all 50 states.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.